Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.
Latagliata R, Stagno F, Annunziata M, Abruzzese E, Iurlo A, Guarini A, Fava C, Gozzini A, Bonifacio M, Sorà F, Leonetti Crescenzi S, Bocchia M, Crugnola M, Castagnetti F, Capodanno I, Galimberti S, Feo C, Porrini R, Pregno P, Rizzo M, Antolino A, Mauro E, Sgherza N, Luciano L, Tiribelli M, Russo Rossi A, Trawinska M, Vigneri P, Breccia M, Rosti G, Alimena G. Latagliata R, et al. Among authors: crugnola m. Neoplasia. 2016 Sep;18(9):536-40. doi: 10.1016/j.neo.2016.07.005. Neoplasia. 2016. PMID: 27659013 Free PMC article.
Survival of elderly patients with acute myeloid leukemia.
Pulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Crugnola M, De Paoli L, Di Bona E, Invernizzi R, Marmont F, Petti MC, Rigolin G, Ronco F, Spadano A, Tosti ME, Visani G, Mele A, Mandelli F. Pulsoni A, et al. Among authors: crugnola m. Haematologica. 2004 Mar;89(3):296-302. Haematologica. 2004. PMID: 15020267
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
Palandri F, Castagnetti F, Iacobucci I, Martinelli G, Amabile M, Gugliotta G, Poerio A, Testoni N, Breccia M, Bocchia M, Crugnola M, Rege-Cambrin G, Martino B, Pierri I, Radaelli F, Specchia G, Pane F, Saglio G, Rosti G, Baccarani M. Palandri F, et al. Among authors: crugnola m. Haematologica. 2010 Aug;95(8):1415-9. doi: 10.3324/haematol.2009.021246. Epub 2010 Mar 19. Haematologica. 2010. PMID: 20305139 Free PMC article.
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G. Latagliata R, et al. Among authors: crugnola m. Hematol Oncol. 2013 Jun;31(2):103-9. doi: 10.1002/hon.2020. Epub 2012 Jul 19. Hematol Oncol. 2013. PMID: 22815278
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.
Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, Fava C, Breccia M, Annunziata M, Stagno F, Tiribelli M, Binotto G, Mansueto G, Gozzini A, Russo S, Cavalli L, Montefusco E, Gugliotta G, Cedrone M, Russo Rossi A, Avanzini P, Pregno P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Storti S, D'Addosio A, Rege-Cambrin G, Luciano L, Alimena G. Latagliata R, et al. Among authors: crugnola m. Drugs Aging. 2013 Aug;30(8):629-37. doi: 10.1007/s40266-013-0088-6. Drugs Aging. 2013. PMID: 23681399
Differences among young adults, adults and elderly chronic myeloid leukemia patients.
Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; GIMEMA CML Working Party. Castagnetti F, et al. Ann Oncol. 2015 Jan;26(1):185-192. doi: 10.1093/annonc/mdu490. Epub 2014 Oct 30. Ann Oncol. 2015. PMID: 25361995 Free article. Clinical Trial.
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.
Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, Perricone M, Breccia M, Ottaviani E, Testoni N, Merli F, Aversa F, Alimena G, Cavo M, Martinelli G, Catani L, Baccarani M, Vianelli N. Palandri F, et al. Among authors: crugnola m. Leukemia. 2015 Jun;29(6):1344-9. doi: 10.1038/leu.2015.87. Epub 2015 Mar 24. Leukemia. 2015. PMID: 25801912
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.
Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, Gobbi M, Carella AM, Gozzini A, Usala E, Cavazzini F, Danise P, Tiribelli M, Binotto G, Pregno P, Bocchia M, Gaidano G, Crugnola M, Bonifacio M, Avanzini P, Celesti F, Guella A, Martino B, Annunziata M, Luciano L, Stagno F, Vallisa D, Pungolino E, Iurlo A, Rambaldi A, Nardiello I, Orlandi E, Gambacorti-Passerini C, Alimena G. Breccia M, et al. Among authors: crugnola m. Leuk Res. 2015 Oct;39(10):1055-9. doi: 10.1016/j.leukres.2015.07.004. Epub 2015 Jul 14. Leuk Res. 2015. PMID: 26282944 Free article.
Dasatinib first-line: Multicentric Italian experience outside clinical trials.
Breccia M, Stagno F, Luciano L, Abruzzese E, Annunziata M, D'Adda M, Maggi A, Sgherza N, Russo-Rossi A, Pregno P, Castagnetti F, Iurlo A, Latagliata R, Cedrone M, Di Renzo N, Sorà F, Rege-Cambrin G, La Nasa G, Scortechini AR, Greco G, Franceschini L, Sica S, Bocchia M, Crugnola M, Orlandi E, Guarini A, Specchia G, Rosti G, Saglio G, Alimena G. Breccia M, et al. Among authors: crugnola m. Leuk Res. 2016 Jan;40:24-9. doi: 10.1016/j.leukres.2015.11.008. Epub 2015 Nov 17. Leuk Res. 2016. PMID: 26643920
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S, De Benedittis C, Polakova KM, Linhartova J, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Klamova H, Salvucci M, Crugnola M, Iurlo A, Albano F, Russo D, Rosti G, Cavo M, Baccarani M, Martinelli G. Soverini S, et al. Among authors: crugnola m. Oncotarget. 2016 Apr 19;7(16):21982-90. doi: 10.18632/oncotarget.8010. Oncotarget. 2016. PMID: 26980736 Free PMC article.
86 results